On how increasing numbers of newer cancer therapies further delay referral to hospice: The increasing palliative care imperative

American Journal of Hospice and Palliative Medicine

Volumn 24, Issue 2, 2007, Pages 126-130

  Mintzer, David M ^a,b   Zagrabbe, Kathryn ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Chemotherapy; Hospice; Palliative care

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; HEALTH CARE DELIVERY; HOSPICE CARE; HUMAN; NEOPLASM; PATIENT CARE PLANNING; PATIENT REFERRAL; RETROSPECTIVE STUDY; TIME; UNITED STATES;

ANTINEOPLASTIC AGENTS; HEALTH SERVICES ACCESSIBILITY; HOSPICE CARE; HUMANS; NEOPLASMS; PATIENT CARE PLANNING; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 34248577791     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909106297363     Document Type: Article

References (12)

1. McCarthy EP, Burns RB, Davis RB, Phillips RS Barriers to hospice care among older patients dying with lung and colorectal cancer. J Clin Oncol. 2003 ; 21: 728-735.
2. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004 ; 22: 315-21.
3. Earle CC, Landrum M., Jeffrey S., Neville B., Weeks J., Ayanian J. Consistency in regional trends of aggressiveness in cancer care near the end of life for elderly Americans 1991-2000. Proc ASCO. 2006 ; 302S.
4. National Hospice and Palliative Care Organization. 2004 Facts and Figures. Available at: www.nhpco.org. Accessed Nov 27, 2006.
5. Shepherd FA, Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 ; 8: 2095-2103.
6. Hanna N., Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 ; 22: 1589-1597.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. New Engl J Med. 2005 ; 353: 123-132.
8. Pfister DG, Johnson DH, Azzoli CG, eg al. American Society of Clinical Oncology Treatment of unresectable non small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004 ;22: 330-353.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology: Non-Small Cell Lung Cancer. Availabale at: www.nccn.org. Accessed Nov 27, 2006.
10. Neuss MN, Jacobson JO, Earle C., et al. Evaluating end of life care: the Quality Oncology Practice Initiative (QOPI) experience. Proc ASCO. 2006 ; 486S.
11. Zimmermann C., Wennberg R. Integrating palliative care: a post-modern perspective. Am J Hosp Palliat Care. 2006 ; 23: 255-258.
12. Casarett D., Abrahm JL Patients with cancer referred to hospice versus a bridge program: patient characteristics, needs for care and survival. J Clin Oncol. 2001 ; 19: 2057-2063.